Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

被引：0
|
作者：
Huihui Jiang
Aiqun Xu
Wanli Xia
Xingyuan Xia
Pulin Li
Binbin Zhang
Ke Zhu
Sijing Zhou
Ran Wang
机构：
[1] The First Affiliated Hospital of Anhui Medical University,Department of Respiratory and Critical Care Medicine
[2] Hefei Second People’s Hospital,Department of General Medicine
[3] The First Affiliated Hospital of Anhui Medical University,Department of Thoracic Surgery
[4] Hefei Third Clinical College of Anhui Medical University,undefined
[5] Hefei Prevention and Treatment Center for Occupational Diseases,undefined
来源：
Cancer Cell International | / 21卷
关键词：
Antitumor drugs; Ipilimumab; Lung cancer; Nivolumab; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
    Jiang, Huihui
    Xu, Aiqun
    Xia, Wanli
    Xia, Xingyuan
    Li, Pulin
    Zhang, Binbin
    Zhu, Ke
    Zhou, Sijing
    Wang, Ran
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [2] Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
    Rangwala, Hussain Sohail
    Fatima, Hareer
    Ali, Mirha
    Sunder, Sailesh
    Devi, Sonia
    Rangwala, Burhanuddin Sohail
    Abbas, Syed Raza
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2024, 36 (01)
  • [3] Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis
    Najah, Qasi
    Almosilhy, Nereen A.
    Ghanm, Thoria Ibrahim Essa
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (02) : 269 - 278
  • [4] Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
    Menshawy, Amr
    Eltonob, Abdelrahman A.
    Barkat, Sarah A.
    Ghanem, Ahmed
    Mniesy, Mahmoud M.
    Mohamed, Ishak
    Abdel-Maboud, Mohamed
    Mattar, Omar M.
    Elfil, Mohamed
    Bahbah, Eshak I.
    Elgebaly, Ahmed
    MELANOMA RESEARCH, 2018, 28 (05) : 371 - 379
  • [5] A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis
    Konwar, Mahanjit
    Bose, Debdipta
    Maurya, Miteshkumar
    Ravi, Renju
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 557 - 576
  • [6] INCIDENCE OF ADVERSE EVENTS AMONG CANCER PATIENTS TREATED WITH NIVOLUMAB WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Vyas, A.
    Patry, E. J.
    Albatal, C.
    Rogala, B.
    VALUE IN HEALTH, 2019, 22 : S61 - S61
  • [7] Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis
    Kamat, Shweta
    Patel, Jay
    Brown, Britny R.
    Vyas, Ami
    CANCER INVESTIGATION, 2022, 40 (09) : 777 - 788
  • [8] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Ravi Potluri
    Sandip Ranjan
    Hitesh Bhandari
    Helen Johnson
    Andriy Moshyk
    Srividya Kotapati
    Experimental Hematology & Oncology, 8
  • [9] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [10] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
12345